NeuroSearch Starts Phase I NS2214 Trials
Danish firm NeuroSearch has started Phase I trials of its antiparkinonism drug NS2214. The first trial will be conducted in the UK.
NS2214 is a dopamine uptake inhibitor which extends the half-life and physiological effect of dopamine by preventing its natural uptake and metabolic breakdown. In patients suffering from Parkinson's disease this is crucial, as dopamine levels are fundamentally low due to diminished numbers of dopamine neurons. This mechanism of action is distinct from other antiparkinsonism drugs, and has proved effective in animal models of the disease. NS2214 is also thought to have a lower potential for side effects than other drugs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze